Last reviewed · How we verify

NCT06131580: ISS-CA-2023

Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome

Status unknown Phase 4 Last updated 14 November 2023
What this trial tests

Phase 4 trial testing Intervention/Treatment in Endogenous Cushing Syndrome in 7 participants. Status unknown.

Timeline
24 October 2023
Primary endpoint
24 November 2025
24 November 2025

Quick facts

Lead sponsorCentre hospitalier de l'Université de Montréal (CHUM)
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment7
Start date24 October 2023
Primary completion24 November 2025
Estimated completion24 November 2025
Sites3 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

Adults 18 to 75, any sex, with Endogenous Cushing Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to continue the evaluation of long-term safety of osilodrostat in 7 Canadian patients who have already received osilodrostat treatment in a previous Global Recordati-sponsored roll-over study and who, based on investigators' judgement, will continue benefiting with its administration.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. 7236 Long Term Extension of Osilodrostat Therapy in Canadian Patients with Cushing’s Disease Benefiting from the LINC 3 and LINC 4 Studies
    · 2024

Verify or expand the search:

Other trials of Intervention/Treatment

Trials testing the same drug.

Other Centre hospitalier de l'Université de Montréal (CHUM) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06131580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing